Iovance Biotherapeutics (IOVA) Q2 2026 earnings summary

Executive summary

• Achieved record Q2 2026 revenue of $99.3M, up 66% year-over-year and 39% sequentially, driven by strong Amtagvi demand and Proleukin sales.

• Gross margin reached 56%, reflecting operational efficiencies, manufacturing scale, and transition to internal iCTC facility.

• Net loss narrowed to $47.3M for Q2 2026, improved from $111.7M in Q2 2025, due to higher sales and reduced R&D and cost of sales.

• Expanded commercial reach with over 95 Authorized Treatment Centers (ATCs), targeting at least 110 by year-end, and broadened international approvals in Australia, Canada, and ongoing reviews in the UK and Switzerland.

• Advanced pipeline with FDA Fast Track for IOV-SAR-201/lifileucel in soft tissue sarcomas, pivotal trial enrollment progress, and next-generation TIL therapies in development.

Financial highlights

• Amtagvi revenue reached $91M, exceeding guidance and up 51% sequentially and 68% year-over-year; Proleukin contributed $9M.

• Total Q2 2026 product revenue: $99.3M vs. $60M in Q2 2025 and $71M in Q1 2026; H1 2026 revenue: $170.7M, up from $109.3M in H1 2025.

• Gross margin improved to 56% from 41% in Q1, benefiting from higher volume and in-house manufacturing.

• R&D expenses declined to $58.9M, marking the fourth consecutive quarter of cost savings.

• Cash and equivalents totaled $304M as of June 30, 2026, funding operations into the second half of 2028.

Outlook and guidance

• FY26 revenue guidance of $350M–$370M under review, with an update expected in Q3.

• Peak U.S. sales assumptions for Amtagvi and Proleukin remain above $1 billion for advanced melanoma.

• Demand trends for Amtagvi and Proleukin expected to strengthen into Q3 and Q4, with continued ATC expansion and international growth.

• Sufficient capital to fund planned operations for at least the next twelve months.

• Anticipates ongoing net losses as investments in R&D and commercialization continue.